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Abbreviations 
 
 
Bcl-2  B-cell chronic lymphocytic leukemia/lymphoma 2 
Cluc  Cypridina luciferase 
COX  cyclooxygenase 
cPGES      cytosolic prostaglandin E synthase 
CRTH2     chemoattractant receptor homologous molecule expressed on Th2 
DJE  Dioscorea japonica extract 
DMBA       7, 12-dimethylbenz[a]anthracene 
DMBADE    7, 12-dimethylbenz[a]anthracene-3, 4-diol-1,2-epoxide 
DP          D-prostanoid receptor 
EPA  eicosapentaenoic acid 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
HE          hematoxylin and eosin 
HETE  hydroxyeicosatetraenoic acid 
HODEs  hydroxyoctadecadienoic acids 
H-PGDS     hematopoietic prostaglandin D synthase 
IL  interleukin 
LC         Langerhans cell 
LPS  lipopolysaccharide  
mPGES-1 microsomal prostaglandin E synthase-1 
mPGES-2 membrane-associated prostaglandin E synthase-2 
MRM        multiple reaction monitoring 
NF-B  nuclear factor-kappa B 
NSAIDs non-steroidal anti-inflammatory drugs 
PG  Prostaglandin 
TPA  12-O-tetradecanoylphorbol 13-acetate 
TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling 
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Introduction 
  
4 
 
 In recent years, Japan has rapidly aging society, and accordingly the number of 
people suffering from various chronic diseases has been increased. Chronic diseases, 
including cancer, cardiovascular diseases, and neurological disease are linked with 
inflammation(1–3). It is known that prostaglandin (PG) E2 is one of the lipid mediators and 
induces an array of chronic inflammation. PGE2 is widely distributed in many tissues and 
organs, and is also involved in several pathophysiological responses such as inhibition of 
gastric acid secretion, pain transmission, neurodegeneration, and carcinogenesis(4,5). 
Arachidonic acid is cleaved from cell membrane by cytosolic phospholipase A2, 
and are converted to PGH2 as a common substrate of prostanoids which are PGD2, PGE2, 
PGF2, prostacyclin (PGI2), and thromboxanA2 (TXA2) (Fig. 1). Cyclooxygenase (COX) 
is a rate-limiting enzyme of prostanoid synthesis, and catalizes two reactions, bis-
dioxygenation of arachidonic acid to PGG2 and the hydroperoxidation of PGG2 to PGH2(6). 
COX has two isozymes, that is, constitutively expressed COX-1 and inducible COX-2. 
The former is important to produce homeostatic prostanoids, whereas, the latter is induced 
under pathophysiological condition and is involved in several diseases(7). The terminal 
PGE2 synthesizing enzyme, PGE synthase (PGES), lies downstream of COX, and 
catalyzes the isomerization of PGH2 to PGE2. PGES has at least three isozymes, 
microsomal PGES-1 (mPGES-1)(8), membrane-associated PGES-2 (mPGES-2)(9,10), and 
cytosolic PGES (cPGES)(11). Among these, mPGES-1 requires glutathione for catalytic 
activity and is usually coupled with COX-2. In several types of cancer cells, COX-2 and 
mPGES-1 are coordinately expressed, and consequently, the excessive PGE2 production 
worsens the symptoms(5,12,13).  
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used a class of 
medicines. NSAIDs are COX inhibitors and are used for pain relief and pyretolysis of 
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patients(13). However, NSAIDs have been reported to cause side effects such as 
gastrointestinal adverse effect and cardiovascular risk(14). NSAIDs-associated 
gastrointestinal effect is thought to arise from the inhibition of the constitutive COX-1. 
Therefore, a selective COX-2 inhibitor was developed with improved safety. However, 
the selective COX-2 inhibition, elevate cardiovascular risk by suppressed COX-2-
dependent biosynthesis of PGI2 in cardiovascular system(15,16). Therefore, mPGES-1 is 
targeted to drug development as a next-generated NSAIDs. Recently, a few mPGES-1 
inhibitors have been found(17), but none have been used clinically. Thus, we have an aim 
 
 
 
Fig. 1. Prostaglandin (PG) synthetic pathway. 
PGH2 is a common substrate for various lipid mediators, and are biosynthesized by specific enzyme 
catalysis into prostaglandins, thromboxane (TX). It binds to specific receptors and exerts various 
physiological effects. COX; cyclooxygenase, PGES; PGE synthase, PGDS; PGD synthase, PGFS; 
PGF synthase, PGIS; PGI synthase, TXS; TX synthase. 
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to find food functionality to decrease PGE2 production without side effects. Such safety 
and mild effects from food will be useful for prevention of chronic inflammation caused 
by PGE2. 
 From these viewpoint, we focused on the PGE2 synthetic pathway, and 
investigated the food functional effects of Dioscorea japonica on the related enzymes of 
PGE2 synthesis. Chapter II describes the effects of Dioscorea japonica on the expression 
of COX-2 and mPGES-1 in human non-small cell lung carcinoma A549 cells. Chapter III 
demonstrates the food functionality of Dioscorea japonica in vivo using squamous cell 
carcinoma of mouse skin. Based on this study, it is proved that Dioscorea japonica may 
be effective for treating inflammation and carcinogenesis.  
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Chapter Ⅱ 
 
Dioscorea japonica extract suppresses the 
expression of cyclooxygenase-2 and microsomal 
prostaglandin E synthase-1 and induces apoptosis 
in lung cancer cells 
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In several types of cancer cells, both COX-2 and mPGES-1 are highly expressed, 
and the consequent excessive production of PGE2 worsens the symptoms(5,12,13). 
Overexpression of COX-2 is commonly observed in lung tumors as well as in many other 
tumors(18,19). Similarly, inducible mPGES-1 expressed preferentially coupling with COX-
2, and the overproduced PGE2 develops cancer(12,20). On the other hand, 15-
hydroxyprostaglandin dehydrogenase (PGDH) is well known for its association with the 
biological inactivation of PGE2, and induces cancer cell apoptosis in human non-small 
cell lung carcinoma cell line, A549(21). NS-398, a selective COX-2 inhibitor(22,23), has 
been found to induce cancer cell apoptosis(24). However, long-term use of NSAIDs cause 
life-threatening side effects, including gastrointestinal injury, renal pathology and 
cardiovascular adverse events(23). 
 Dioscorea japonica, a wild yam, is a relative of the Dioscoreaceae family native 
to Japan. Dioscoreaceae yam tubers are usually edible and are rich in many nutrients 
including carbohydrates, essential amino acids, vitamin C, minerals, and physiologically 
active components such as glycoprotein, polysaccharides, and steroidal saponins(25–28). It 
is well known that Dioscorea japonica is good for nutritional fortification, and it has also 
been shown to mediate gastric mucosal protection and digestive enhancement. However, 
the other physiological effects of Dioscorea japonica have not been completely 
elucidated. 
 The aim of this study was to explore the novel functional effects of Dioscorea 
japonica on the regulation of the PGE2 synthesis pathway. We also examined the 
possibility that Dioscorea japonica exerts anti-tumoral effects in lung cancer cells via 
down-regulation of PGE2 synthesizing enzymes.  
9 
 
MATERIALS AND METHODS 
 
 
Preparation of Dioscorea japonica powder and extract 
Dioscorea japonica was obtained from Autoraimu Yoshio Ltd. (Niimi, Japan). 
Dioscorea japonica was pared away the outer skin and was dried under 40°C. The ground 
Dioscorea japonica was prepared to uniform powders through 250 m mesh. The 
powders were eluted with 20–80% ethanol (v/v, EtOH), and the extracts were 
immediately dried-up with nitrogen gas and were completely filling with the gas protect 
oxidation. They were stored at -80°C until used for the experiments. When the Dioscorea 
japonica extract (DJE) was added to the medium for cell culture, the dried DJE was added 
to the medium for cell culture, the dried DJE was re-dissolved in DMSO as a vehicle. The 
final concentration of DMSO was 0.1% in the medium for control cells and DJE-treated 
cells. 
 
Cell culture  
Human non-small cell lung carcinoma cell line A549 and human colon 
carcinoma cell line (ATCC CCL-185) and human colon carcinoma cell line Caco-2 
(ECACC 86010202) were obtained from RIKEN BioResource Center (Tsukuba, Japan). 
The cells were cultured in Dulbecco's modified Eagle’s medium (Sigma, MO, USA) 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 g/ml 
streptomycin. The cells were treated with 0–100 g/ml DJE in dimethyl sulfoxide, 0–10 
M diosgenin (Sigma, St. Louis, MO) in dimethyl sulfoxide or were added the only 
vehicle as a control. 
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RNA purification and quantitative RT-coupled real-time PCR 
A549 or Caco-2 cells after the treatment for 24h were collected and the total 
RNA was isolated using the acid guanidinium thiocyanate procedure and analyzed for 
gene expression by real-time quantitative RT-PCR (iQ5 real-time PCR system, Bio-Rad, 
CA, USA). After converting total RNA to cDNA using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA, USA), quantitative PCR was performed 
using Eva Green-Comparative Ct method (Bio-Rad). The following primer pairs were 
used for amplification of COX-2, mPGES-1, B-cell chronic lymphocytic 
leukemia/lymphoma 2 (Bcl-2) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH): 5’-TGCATTCTTTGCCCAGCACT-3’ (COX-2 forward), 5’-AAAGGCG 
CAGTTTACGCTGT-3’ (COX-2 reverse), 5’-TGATCACACCCACAGTTGAGC-3’ 
(mPGES-1 forward), 5’-TGATGATGGCCACCACGTA-3’ (mPGES-1 reverse), 5’-TG 
GATGACTGAGTACCTGAA-3’ (Bcl-2 forward), 5’-CCAGGAGAAATCAAACAG 
AG-3’ (Bcl-2 reverse), 5’-CGACATCCCTCCAAAATCAA-3’(GAPDH forward), and 
5’-TTCACACCCATGACGAACAT-3’ (GAPDH reverse). The cycling conditions were 
30 s at 95°C, followed by 40 cycles of 95°C for 5 s and 60°C for 10 s. Expression levels 
of COX-2, mPGES-1 and Bcl-2 mRNAs were normalized to those of GAPDH mRNA. 
The relative expression levels were shown against control and were mean ± S.D. of 5 
separate experiments.  
 
Western blotting 
Collected A549 cells (5 x 105 cells) after the treatment with or without DJE for 
48h were sonicated in 100 l of 10mM Tris-HCl (pH 7.6) and then were centrifuged at 
10,000 x g, and the supernatant (30 g protein/well) was subjected to 10% sodium 
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dodecyl sulfate-polyaclylamidegel electrophoresis, and were transferred 
electrophoretically to a Hybond-P polyvinylidene difluoride membrane (Amersham 
Biosciences, Buckinghamshire, UK). After treatment with blocking reagent (Roche, 
Penzberg, Germany), the membrane was incubated with rabbit anti-COX-2 antibody 
(1:1000, Immuno-Biological Laboratories Co., Ltd., Gunma, Japan), rabbit anti-mPGES-
1 antibody (1:1000, Cayman Chemical Co. Ann Arbor, MI) or rabbit anti -actin antibody 
(1:1000, Cell Signaling Technology, Boston, MA). The immunoreactive proteins were 
visualized using BM chemiluminescence Western blotting kit (Roche). The density of 
each protein bands was analyzed with Fujifilm Multi Gauge version 3.0 software 
(Fujifilm, Tokyo, Japan). Protein concentration was determined using a BCA protein 
assay kit (Thermo Scientific Inc., Rockford, IL). 
 
COX activity assay 
COX activity was analyzed as described previous report(29). The lysates were 
incubated with 100mM Tris-HCl buffer (pH 7.4) containing 25mM linoleic acid, and the 
products were analyzed by reversed-phase HPLC using a COSMOSIL 5C18-MS-II 
column (5 mm particle, 4.6x250mm, Nacalai Tesque, Kyoto, Japan) with a solvent system 
of methanol/water/acetic acid (80:20:0.01, v/v). The produced 9- and 13- 
hydroxyoctadecadienoic acids (HODEs) which cochromatographed on reverse-phase 
HPLC as a single peak were quantified by the comparison of the area of the peak with 
that of an internal standard, 15-hydroxyeicosatetraenoic acid (HETE). 
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Enzyme immunoassay 
 After the treatment with or without DJE by 50% ethanol (100 g/ml) for 48h, 
arachidonic acid (10 M) was added to the culture medium of A549 cells. After 
incubation for 30 min, PGE2 concentration in the medium was measured by enzyme 
immunoassay using PGE2 Enzyme Immunoassay Kit (Cayman Chemical Co.) as 
instructed by the manufacturer. 
 
Immunocytochemistry 
 The intracellular localization of transcription factor nuclear factor-B (NF-B) 
was analyzed by fluorescence immunocytochemistry. After the treatment for 48h, the cell 
was fixed with 4% paraformaldehyde for 10 min and 0.5% ethanol for 2 min. After 
blocking with Block Ace (Dainippon Seiyaku, Osaka, Japan), the cells were incubated 
with anti-NF-B p65 (C22B4) rabbit antibody (Cell Signaling Technology), and then 
were incubated with Cyanine (Cy) 3-labeled donkey anti-rabbit IgG (1:400, Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA). The cells were counter stained 
with 4', 6-diamidino-2-phenylindole (DAPI). The sections were analyzed using confocal 
laser scanning light microscopy (CLSM, FV1000, Olympus Corporation, Tokyo, Japan). 
 
Promoter assay 
 COX-2 promoter assay was carried out as described previously(30). COX-2/Cluc 
plasmid with COX-2 promoter region and Cypridina luciferase (Cluc) as a reporter gene 
was transfected into A549 cells. After the transfection, A549 cells were treated with 0.1 
M 12-O-tetradecanoylphorbol 13-acetate (TPA) and with or without DJE for 48h, and 
the luciferase activity in the culture medium was measured using BioLux™ Cypridina 
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Luciferase Assay Kit (New England BioLabs Inc., MA). A549 cells without the treatment 
of TPA and DJE was used as a control. 
 
TUNEL assay 
After treatment of with or without DJE for 48h, terminal deoxynucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL) assay was carried out 
identification of the extent of DNA fragmentation in A549 cells, using Peroxidase In Situ 
Apoptosis Detection Kit (EMD Millipore, Billerica, MA) as instructed by the 
manufacturer. TUNEL positive reactivity was observed with a light microscope 
(ECLIPSE 80i; Nikon Co., Tokyo, Japan). 
 
Statistics 
 Data were statistically evaluated by unpaired Student’s t-test (Fig. 3B and 5) and 
ANOVA with Bonferroni’s (Fig. 3A, 4B and 7A) or Dunnett’s (Fig2, 6B and 8) post hoc 
test at significance level of p<0.05 or 0.01.  
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RESULTS 
 
Dose-dependent effect of DJE on the expression of COX-2 and mPGES-1 
in A549cells 
COX-2 and mPGES-1 are constitutively and highly expressed in human lung 
carcinoma A549 cells. A549 cells were treated with DJE by 50% ethanol at 0.1-100 g/ml 
concentration, and mRNA expression of COX-2 and mPGES-1 in the cells was analyzed 
by real-time PCR. DJE suppressed the expression of COX-2 and mPGES-1 in a dose-
dependent manner (Fig. 2). Treatment with 100 g/ml DJE significantly decreased 
mRNA levels of COX-2 and mPGES-1 to 27% and 46% compared with the control, 
respectively. Therefore, this concentration of DJE (100 g/ml) was used for the following 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Dose-dependent effect of DJE on the expression of COX-2 and mPGES-1 in A549 cells. 
DJE by 50% ethanol (0–100 g/ml) was added to A549 cells. mRNA expression of COX-2 (open 
column) and mPGES-1 (closed column) was measured by real-time PCR, as described in the 
Materials and Methods section. The values are represented as a relative value against 0 g/ml 
extract-treated cells and represent mean ± S.D. of 5 separate experiments. *p<0.05 compared with 
treatment with 0 g/ml extract. 
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experiments. Addition of DJE made no significant difference on cell proliferation in the 
experimental period. 
 
Suppression of the expression of COX-2 and mPGES-1 by DJE 
 Among the water-soluble extract of Dioscorea japonica and DJE by 20, 50, and 
80% ethanol, DJE by 50% ethanol was most effective in suppressing the expression of 
COX-2 and mPGES-1 in A549 cells, whereas the water-soluble extract had little effect 
(Fig. 3A). Further, in human colon carcinoma model Caco-2 cells, treatment with DJE 
led to the suppression of COX-2 and mPGES-1 mRNAs to approximately 67% compared 
with the control (Fig. 3B). 
 
 
 
 
Fig. 3. Effect of water-soluble and Ethanol extract of Dioscorea japonica on the expression of 
COX-2 and mPGES-1 in A549 cells (A) and Caco-2 cells (B).  
Water-soluble or Ethanol (20, 50, and 80%) extract of Dioscorea japonica (100 g/ml) was added 
to A549 cells (A), and the DJE by 50% ethanol (100 g/ml) was added to Caco-2 (B). mRNA 
expression of COX-2 (open column) and mPGES-1 (closed column) was measured using real-time 
PCR. The values are represented as a relative value control cells and represent mean ± S.D. of 5 
separate experiments. *p<0.01 compared with the control. 
 
16 
 
After treatment with DJE by 50% ethanol for 48 h, COX-2 and mPGES-1 protein  
 
 
Fig. 4. Changes in protein expression of COX-2 and mPGES-1 after treatment with DJE. 
The protein expression levels of COX-2 and mPGES-1 were analyzed by Western blotting. The 
detected COX-2 and mPGES-1 proteins (30 g total protein/well) were visualized as 
approximately 70 and 16 kDa bands, respectively (A). The density of each protein band was 
compared in 3 separate experiments with -actin (approximately 45 kDa) as a control (B). *p<0.1 
compared with the control. 
 
 
 
Fig. 5. Decrease in COX activity (A) and PGE2 production (B) after treatment with DJE.  
COX activity after the treatment without (open column) or with (closed column) DJE (100 
g/ml) was measured. Supernatants obtained from the centrifugation (10,000 × g) of lysates from 
A549 and Caco-2 cells were used as enzyme sources for measurement of COX activity. The 
supernatants were incubated with 25 mM linoleic acid at 24°C for 5 min in the standard COX 
reaction mixture and the products were quantified using reversed-phase HPLC, as described in 
the Materials and Methods section. PGE2 released in the culture medium of A549 cells was 
quantified by enzyme immunoassay. The values represent mean ± S.D. of 5 separate 
experiments. *p<0.05 and **p<0.01 compared with the control. 
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After treatment with DJE by 50% ethanol for 48 h, COX-2 and mPGES-1 protein 
levels were decreased to 1.37 and 0.82, respectively, compared with the control (2.67 and 
5.58) in A549 cells (Fig. 4). 
 
Changes in COX activity and PGE2 production by DJE treatment 
COX activity was assayed by quantifying the metabolism of linoleic acid to 
HODEs using A549 and Caco-2 cells lysates as enzyme sources, as described in the 
Materials and Methods section. COX catalyzes the metabolism of arachidonic acid to 
PGH2 and linoleic acid to 9- and 13-HODEs(31). In the present study, linoleic acid was 
used as the substrate because it presents several advantages over arachidonic acid. 
 
 
 
 
 
Fig. 6. Changes in NF-B localization (A) and COX-2 promoter activity (B) after DJE 
treatment in A549 cells.  
Localization of the transcription factor NF-B (red) and DAPI (blue, nuclear counterstain) was 
visualized by confocal laser scanning microscopy (A). Scale bar indicates 50 m. Cluc reporter 
plasmid with COX-2 promoter was used for the promoter activity assay, as described in the 
Materials and Methods section (B). TPA (0.1 M) was used as an inducer of COX-2 expression. 
The values are represented as a relative value against cells without TPA and DJE and represent 
mean ± S.D. of 3 separate experiments. ap<0.01 compared with the control without TPA and DJE 
and bp<0.01 compared with TPA treatment without DJE. 
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HODEs metabolized from linoleic acid were stable and these are quantified by the typical 
reverse-phase HPLC analysis for low-molecular-weight lipids, although PGH2 
synthesized from arachidonic acid is highly unstable and is immediately and non-
enzymatically metabolized to several PGs. After treatment with DJE for 48 h, COX 
activity was decreased to 46% (39 pmol/min/mg protein) and 50% (27 pmol/min/mg 
protein) when compared with each control in A549 cells and Caco-2 cells, respectively 
(Fig. 5A). 
PGE2 production was quantified by enzyme immunoassay. Released PGE2 in the 
culture medium of A549 cells was also significantly decreased to 31% (647 pg/ml) by 
DJE treatment (Fig. 5B). 
 
Translocation of NF-B and suppression of COX-2 promoter activity by 
DJE 
 After treatment with DJE by 50% ethanol (100 g/ml) for 48 h, localization of 
the transcription factor NF-B was analyzed by immunocytochemistry (Fig. 6A). In some 
pathological conditions such as cancer and inflammation, NF-B is translocated from the 
cytosol to the nucleus and plays a key role in regulating COX-2 transcriptional activity. 
NF-B immunoreactivity merged with the nuclear counterstain DAPI in control A549 
cells (Fig. 6A top panels). The findings indicate that NF-B is constitutively localized in 
the nucleus in A549 cancer cells, which exhibit high levels of COX-2. In contrast, DJE 
treatment induced the translocation of NF-B from the nucleus to the cytosol (Fig. 6A 
bottom panels). Additionally, the COX-2 promoter activity was measured using COX-
2/Cluc plasmid with Cypridina luciferase reporter gene (Fig. 6B). TPA (0.1 M), a COX-
2 inducer, increased luciferase activity by approximately 4-fold, and addition of DJE 
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significantly decreased TPA-induced luciferase activity to a level similar to that of the 
control. 
 
Suppression of Bcl-2 mRNA expression and induction of apoptosis by DJE  
 mRNA expression of the anti-apoptotic factor Bcl-2 was suppressed after 
treatment with DJE for 24 h (Fig. 7A). Compared with the control, DJE by 50% ethanol 
significantly decreased Bcl-2 mRNA levels to 18%. 
 Further, in situ detection of apoptotic cells with TUNEL method revealed a large 
number of brown-colored positive A549 cells after DJE treatment, although colored cells 
were hardly observed in the control cells (Fig. 7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Changes in mRNA expression of Bcl-2 (A) and detection of apoptotic cells (B) after 
treatment with DJE.  
mRNA expression of the anti-apoptotic factor Bcl-2 was measured by real-time PCR (A). The 
values are represented as a relative value control cells and represent mean ± S.D. of 5 separate 
experiments. *p<0.01 compared with the control. In situ apoptotic cells were detected by TUNEL 
method, as described in the Materials and Methods section (B). TUNEL-positive cells were brown-
colored. Scale bar indicates 20 m. 
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Effect of diosgenin on the expression of COX-2 and mPGES-1 in 
A549cells 
 Diosgenin is a major steroidal saponin constituent and is found more abundantly 
in Dioscorea japonica compared with other food substances. Diosgenin suppressed COX-
2 expression in A549 cells in a dose-dependent manner (0–10 M), and 10 M diosgenin 
reduced COX-2 expression to 46% compared with the control (Fig. 8). In contrast, 
diosgenin did not have a significant effect on the expression of mPGES-1. 
 
 
 
 
 
 
 
Fig. 8. Effect of diosgenin on the expression of COX-2 and mPGES-1 in A549 cells. 
Diosgenin (0.1–10 M) was added to A549 cells. mRNA expression of COX-2 (open column) and 
mPGES-1 (closed column) was measured by real-time PCR, as described in the Materials and Methods 
section. The values are represented as a relative value against 0 M diosgenin-treated cells and 
represent mean ± S.D. of 5 separate experiments. *p<0.05 compared with treatment with 0 M 
diosgenin.  
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DISCUSSION 
 
 
Of all cancers, lung cancer has the highest mortality, and the 5-year survival rate 
is very low. Therefore, new approaches for the management and prevention of lung cancer 
are highly essential. In our current study, we attempted to investigate the preventive 
effects of natural food products on lung cancer by targeting the PGE2 synthesis pathway. 
We demonstrated that DJE suppressed the expression of COX-2 and mPGES-1 and 
exerted anti-carcinogenic effects in human lung carcinoma A549 cells. 
 Our data show that DJE suppressed mRNA and protein expressions of COX-2 
and mPGES-1 and consequently decreased COX activity and PGE2 production. 
Furthermore, DJE induced the translocation of NF-B, the typical transcription factor of 
COX-2, from the nucleus to the cytosol in A549 cells (Fig. 6A). This finding indicated 
that DJE regulates COX-2 signal transduction pathway mediating COX-2 induction. 
Consistent with this hypothesis, the transcriptional activity of COX-2 was significantly 
decreased by DJE, as shown using an expression plasmid containing COX-2 promoter 
with a Cluc reporter gene (Fig. 6B). In lung cancer cells, inhibition of COX-2 by 
trichostatin A(32), a histone deacetylase inhibitor, or celecoxib(33), a NSAID that acts as a 
selective COX-2 inhibitor, correlates with a decrease in PGE2 production. Such inhibitors 
suppress tumor growth with decreasing the levels of Bcl-2 which is the anti-apoptotic 
factor and is the most important factor associated with a decrease in PGE2 
production(22,34,35). Our results also showed that DJE suppressed the expression of COX-
2 and mPGES-1, which are key enzymes for PGE2 production, and induced apoptosis 
with suppression of Bcl-2 in cancer cells. 
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Several phytochemicals from other natural products, such as resveratrol(36), 
humulon(37), chrysin(38), and 6-shogaol(39) have been shown to suppress the expression of 
COX-2. Additionally, the suppressive effect on mPGES-1 expression by phytochemicals 
are known to sulforaphane(40) and curcumin(41). Diosgenin, an aglycone of the steroidal 
saponin dioscin that is abundantly found in Dioscorea japonica, may be one of the 
candidate compounds having the functional effects observed in our study. There are some 
reports that support our results that diosgenin may have suppressive effects on the signal 
transduction pathway mediating COX-2 induction. Diosgenin inhibits Akt signaling and 
its downstream targets, NF-B and Bcl-2, in human breast cancer cells(42). In addition, 
diosgenin has been shown to induce apoptosis in HepG2 and HEL cells(43,44). In a mouse 
model for colon cancer, diosgenin was shown to decrease gene expression of 
inflammatory cytokines such as IL-1 and IL-12 and to prevent colon carcinogenesis(45). 
In the present study, the effect of diosgenin (0–10 M) on the expression of COX-2 and 
mPGES-1 in A549 cells was investigated. Diosgenin suppressed COX-2 expression in a 
dose-dependent manner, and COX-2 expression was decreased to 47% by 10 M 
diosgenin (Fig. 8). However, the effect of diosgenin on COX-2 expression was lower than 
that of DJE by 50% ethanol (100 g/ml DJE), which decreased COX-2 expression to 27% 
(Fig. 3A). On the other hand, diosgenin did not have a significant effect on mPGES-1 
expression. This suggests that multiple components in DJE mediate its ability to inhibit 
the expression of COX-2 and mPGES-1, leading to anti-inflammation and anti-
carcinogenesis, suggesting there may be a novel functional component in DJE that has 
yet to be identified. 
Our result may be important in understanding the preventive effects of Dioscorea 
japonica against the chronic disease that are mediated by PGE2, although additional in 
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vivo studies are required to address the physiological significance of our findings. 
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Chapter III 
 
Preventive effect of Dioscorea japonica on 
squamous cell carcinoma of mouse skin involving 
down-regulation of prostaglandin E2 synthetic 
pathway 
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Skin cancers are caused by any kinds of environmental carcinogens, 
inflammatory agents, and tumor promoters. It has been known that inflammation 
associates with development in pre-malignant and malignant transformation of cells and 
induces tumor development(2,46). 
In skin cancers caused by some stimuli such as ultraviolet light and chemicals, 
induced COX-2 hyperproduces PGE2(47–49). Previous reports using COX-2 inhibitor(50) 
and COX-2 deficient mouse(51) demonstrate the prevention of tumor development in 
squamous cell carcinoma of the mouse skin. COX-2 is functionally coupled with  
mPGES-1 for PGE2 synthesis in pathophysiological conditions(52), and these enzymes are 
overexpressed in various tumors and inflammation(13,52–54). 
Chapter II demonstrated for the first time that DJE suppressed the expression 
of COX-2 and mPGES-1, resulting PGE2 decrease induces cancer cell apoptosis in lung 
cancer A549 cells(55). The aim of a next study is the verification of the effects of Dioscorea 
japonica on inflammation and carcinogenesis via the suppression of COX-2 and  
mPGES-1 in vivo. In this chapter, therefore, we demonstrate the effects using a two-stage 
cutaneous chemical carcinogenesis model of mouse skin(56).  
26 
 
MATERIALS AND METHODS 
 
 
Animal rearing conditions and the method of preparing a model of 
squamous cell carcinoma 
All protocols were approved by the Exclusive Committee on Animal Research 
at Okayama Prefectural University and the research was conducted in conformity with 
the Public Health Service (PHS) policy. Seven-week-old male Balb/c mice had free access 
to drinking water and food. Mice were fed a powder diet (CRF-1; Oriental Yeast Co. Ltd., 
Tokyo, Japan) with or without (w/w) 1% or 10% Dioscorea japonica powder. Dioscorea 
japonica was obtained from Autoraimu Yoshio Ltd. (Niimi, Japan). The outer skin of 
Dioscorea japonica was pared away, and it was dried and pulverized at 40°C. Feed 
consumption was measured twice a week, and weight was measured every second week. 
According to the procedure of Modi et al.(56), a squamous cell carcinoma model was 
induced by topically applying the following to each mouse: firstly, 200 μL of 2 mM 7,12-
dimethylbenz[a]anthracene (DMBA, as an initiator, Sigma-Aldrich, St. Louis, MO); then, 
after one week, 200 μL of 80 μM 12-O-tetradecanoylphorbol-13 acetate (TPA, as a 
promoter, Sigma-Aldrich) twice per week for 22 weeks (Fig. 9). Numbers and volumes 
of cutaneous papillomas were measured. Mice in three experimental groups were applied 
with 100 L of 0.05, 0.5 or 5 mg of Dioscorea japonica extract eluted from the powder 
with 50% ethanol 30 min before the application of TPA, and fed a basal diet (CRF-1) 
without Dioscorea japonica powder.  
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Quantitative reverse transcriptase (RT)-PCR 
The gene expression was analyzed by quantitative RT-PCR (iQ5 real-time PCR 
system, Bio-Rad, Hercules, CA) using cDNA prepared from isolated total RNA. The 
quantitative PCR was performed using SsoAdvanced Universal SYBR Green Supermix 
(Bio-Rad), and the following PCR primer pairs: Ptgs1 (COX-1), 5′-CTTTGCA 
CAACACTTCACCCACC-3′ (forward) and 5′-AGCAACCCAAACACCTCCTGG-3′ 
(reverse); Ptgs2 (COX-2), 5-GCATTCTTTGCCCAGCACTT-3 (forward) and 5-AGA 
CCAGGCACCAGACCAAAGA-3 (reverse); Ptges (mPGES-1), 5-CTGCTGGTCAT 
CAAGATGTACG-3 (forward) and 5-CCCAGGTAGGCCACGGTGTGT-3 (reverse); 
Ptges2 (membrane-associated PGES-2 (mPGES-2)), 5′-AAGACATGTCCCTTCTGC-3′ 
(forward) and 5′-CCAAGATGGGCACTTTCC-3′ (reverse); Ptges3 (cytosolic PGES 
(cPGES)), 5′-AGTCATGGCCTAGGTTAAC-3′ (forward) and 5′-TGTGAATCA 
TCATCTGCTCC-3′ (reverse); Ptgds2 (hematopoietic PGD synthase (H-PGDS)), 5′-CA 
CGCTGGATGACTTCATGT-3′ (forward) and 5′-AATTCATTGAACATCCGTCTT-3′ 
(reverse); Il1b (interleukin (IL)-1, 5-GTCACAAGAAACCATGGCACAT-3 (forward) 
and 5-GCCCATCAGAGGCAAGGA-3 (reverse); Il6 (IL-6), 5-CTGCAAGA 
GACTTCCATCCAGTT-3 (forward) and 5-AGGGAAGGCCGTGGTTGT-3 (reverse); 
and gapdh (glyceraldehyde 3-phosphate dehydrogenase (GAPDH)), 5-TGAACGGGA 
AGCTCACTGG-3 (forward) and 5-TCCACCACCCTGTTGCTGTA-3 (reverse). The 
relative expression levels were shown against normal controls and represent mean ± SD. 
 
Pathohistological and immunohistochemical analyses 
Prepared paraffin-embedded sections of mouse skin were used for hematoxylin 
and eosin (HE) staining and immunohistochemical staining. For single immunolabeling, 
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sections were treated with 3% hydrogen peroxide to block endogenous peroxidase activity, 
and were blocked with 12.5% Block Ace (DS Pharma Biomedical Co., Ltd., Tokyo, 
Japan) to block nonspecific bindings. For immunolabeling, we used the following first 
antibodies: goat anti-COX-2 antibody (1:50, catalogue no. sc-1745, lot no. E102, Santa 
Cruz Biotechnology, Inc., Santa Cruz CA), rabbit anti-mPGES-1 antibody (1:500, 
catalogue no. 160140, lot no. 0436398-1, Cayman Chemical Co., Ann Arbor, MI), rabbit 
anti-H-PGDS antiserum (1:1000, catalogue no. 10004348, lot no. 0451181-1, Cayman 
Chemical Co.), rat anti-Ly-6G/Ly-6C (Gr-1) antibody (1:500, a marker of neutrophils; 
catalogue no. 108413, lot no. B141536, BioLegend, San Diego, CA), and mouse anti-
Langerin/CD207 antibody (1:1000, a marker of Langerhans cells; catalogue no. 
DDX0361P-50, lot no. DDX0361-009, DENDRITICS, Lyon, France), and the following 
second antibodies: biotinylated anti-goat, biotinylated anti-rabbit, Cy3-labeled donkey 
anti-goat, FITC-labeled donkey anti-rabbit, FITC-labeled donkey anti-goat, FITC-labeled 
donkey anti-rat, FITC-labeled donkey anti-mouse IgGs (1:400, biotinylated IgGs from 
Vector Laboratories, Burlingame, CA, and fluorescein-labeled IgGs from Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA). The biotin-labeling was enhanced 
by ABC Elite kit (Vector Laboratories) and was visualized in 50 mM Tris (pH 7.6) 
containing 0.1% 3,3-diaminobenzidine tetrahydrochloride (DAB) and 0.01% hydrogen 
peroxide at 37C. The fluorescein-labeled sections were examined by confocal laser 
scanning light microscopy (CLSM, Fluoview FV1000, Olympus Co., Tokyo, Japan). 
 
Electrospray ionization mass spectrometry (ESI-MS) 
All procedures were performed as described previously(57). Tissues were 
homogenized with a Polytron homogenizer in methanol and were incubated overnight. 
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As internal standards for determination, 100 pmol of d5-labeled eicosapentaenoic acid 
(EPA) and d8-labeled 15-hydroxyeicosatetraenoic acid (15-HETE), were added to the 
samples. The lipids in the sample were extracted using Oasis HLB cartridges (Waters, 
Milford, MA), and were dried up under nitrogen gas. The analysis was performed using 
a 4000Q-TRAP quadrupole-linear ion trap hybrid mass spectrometer (AB Sciex, 
Framingham, MA) with LC (NexeraX2 system; Shimadzu Co., Kyoto, Japan). The 
sample was applied to a C18 column (Kinetex C18, 2.1 x 150 mm, 1.7 m, Phenomenex, 
Inc., Torrance, CA) coupled for ESI-MS/MS. For analyses of fatty acids, the samples are 
applied to a column and separated by a step gradient with mobile phase A 
(acetonitrile:MeOH:water = 1:1:1 (v/v/v) containing 5 M phosphoric acid and 1 mM 
ammonium formate) and mobile phase B (2-propanol containing 5 M phosphoric acid 
and 1 mM ammonium formate) at a flow rate of 0.2 ml/min at 50°C. Whereas, for analyses 
of oxidized fatty acids, the samples are applied to a column and separated by a step 
gradient with mobile phase C (water containing 0.1 % acetic acid) and mobile phase D 
(acetonitrile:MeOH = 4:1; v/v) at a flow rate of 0.2 ml/min at 45°C. Signature ion 
fragments for each targeted lipid were monitored and quantified by a multiple reaction 
monitoring (MRM) method. Identification was conducted using MRM transition(58) and 
retention times. Quantification was performed based on peak area of the MRM transition 
and the calibration curve obtained with the authentic standard for each compound. 
 
Effect of diosgenin on the expression of COX-2 and mPGES-1 in RAW264 
cells 
 Mouse macrophage-like RAW264 cells were obtained from RIKEN 
BioResource Center (Tsukuba, Japan). The cells were cultured in Dulbecco's modified 
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Eagle’s medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 
100 g/ml streptomycin. RAW264 cells were incubated with or without 100 nM 
diosgenin. After the incubation for 3h, the cells were stimulated by 2.5 g/mL 
lipopolysaccharide (LPS) for 6h. mRNA expression of Ptgs2 and Ptges was measured by 
quantitative RT-PCR. 
 
Statistics 
Data were statistically evaluated by ANOVA with Bonferroni’s or Dunnett’s 
post-hoc test at significance level of p<0.01 or p<0.05.  
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Fig. 9. Treatment scheme and comparison of food intake and body weight among the 
experimental groups. 
Seven-week-old male Balb/c mice were treated with the respective regimens according to the 
treatment scheme (A). Animals were divided into four experimental groups: group “normal control” 
was given control diet and treatment with vehicle; group “carcinogenic control” was given normal diet 
and treatment with DMBA/TPA; group “Dioscorea japonica feeding” (D. japonica feeding) was given 
1% or 10% Dioscorea japonica powder (w/w) containing diet and treatment with DMBA/TPA; group 
“Dioscorea japonica extract topical application” (DJE-application) was given a normal diet and 
treatment with DMBA/TPA and 0.05-5 mg of Dioscorea japonica extract/100 l of 50% ethanol. Food 
intake (B) and body weight (C) were recorded. The values represent mean ± SD. 
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RESULTS 
 
 
Comparison of tumor formation among the experimental groups 
In the present model of squamous cell carcinoma, DMBA and TPA were used as 
initiator and promoter, respectively. DMBA is incorporated into Langerhans cells (LCs) 
 
 
 
Fig. 10. Comparison of tumor formation among experimental groups.  
Representative images of mice from each experimental group after 22 weeks of tumor induction are 
shown in A. Tumors are identified to enable comparison between normal skin and swelling tissue, 
and tumor number (B) and volume (C) are indicated. The values represent mean ± SD of 6 mice per 
group; *p<0.01 compared with the carcinogenic control. 
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in the epidermis, and is metabolized to DMBA-3,4-diol-1,2-epoxide (DMBADE)(56). 
DMBADE is known to strongly induce keratinocytes during carcinogenesis(56,59).  
Tumor formation was measured in the experimental groups including Dioscorea 
japonica feeding group and DJE topical application group (Fig. 10). Throughout the 
experiment, food intake and body weight were not significant differences among the 
experimental groups (Fig. 9B and C). After 22 weeks of tumor induction, there was no 
noticeable difference in tumor numbers between the experimental groups with the 
exception of the normal control (Fig. 10B and Fig. 11A). However, the tumor volumes 
were significantly decreased in the Dioscorea japonica feeding and DJE topical 
application groups (Fig. 10A, C, and Fig. 11B). These data indicate that Dioscorea 
japonica treatment is more beneficial for tumor volumes than tumor numbers. Thus, 
Dioscorea japonica may inhibit tumor growth. 
 
 
 
Fig. 11. Dose-dependent effects of D. japonica feeding and DJE-application on tumor formation. 
Tumor number (A) and volume (B) were measured. The values represent mean ± SD of 3-4 mice per 
group; *p<0.01 compared with the carcinogenic control. N.D.; not detected. 
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Suppression of COX-2, mPGES-1, inflammatory cytokines, and decrease 
of PG products by Dioscorea japonica treatment 
To examine the effect of Dioscorea japonica administration on mRNA 
expression in mouse skin (Fig. 12), Ptgs1 (COX-1), Ptgs2 (COX-2), Ptges (mPGES-1),  
 
 
 
 
 
Fig. 12. Changes in gene expression. 
In normal or carcinogenic controls, 10% Dioscorea japnonica feeding, and 5mg DJE topical 
application, mRNA expression of Ptgs1 (COX-1), Ptgs2 (COX-2), Ptges (mPGES-1), Ptges2 
(mPGES-2), Ptges3 (cPGES), Ptgds2 (H-PGDS), Il1b (IL-1), and Il6 (IL-6) was analyzed by 
quantitative RT-PCR. Expression levels of each mRNA were normalized to that of gapdh (GAPDH) 
mRNA. The relative expression levels are shown against normal control levels and represent mean 
± SD of 6 mice per group; p<0.01 compared with anormal controls and bcarcinogenic controls. 
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Ptges2 (mPGES-2), Ptges3 (another cytosolic PGE2 synthase, cPGES), Ptgds2 (PGD2 
synthesizing enzyme, H-PGDS), and inflammatory cytokines Il1b (IL-1 and Il6 (IL-6) 
were analyzed by quantitative RT-PCR. In the carcinogenic control mice, Ptgs2, Ptges, 
and Il1b increased approximately 25-fold compared with the normal control mice. On the 
other hand, Dioscorea japonica feeding led to the suppression of Ptgs2, Ptges, and Il1b 
mRNA to 47%, 46%, and 15% compared with the carcinogenic control, respectively. In 
addition, DJE topical application decreased mRNA levels of these genes to 35%, 43%, 
and 26% compared with the carcinogenic control, respectively. Moreover, mRNA 
expression of Il6 in Dioscorea japonica treatment was also decreased to almost the same 
level to that in normal control. Additionally, Dioscorea japonica treatment did not affect 
to the expression of Ptgds2 and Ptges3, although the expression of them was induced to 
approximately 5-fold and 2.5-fold, respectively in the carcinogenic control mice (Fig. 12). 
On the other hand, the expression of Ptgs1 and Ptges2 was not affected among all 
 
 
 
 
 
Fig. 13. Changes in amounts of PGs. 
The production of PGE2, PGD2, PGF2, and arachidonic acid was analyzed by ESI-MS. Amounts 
indicated represent mean ± SD of 10 samples per group; p<0.01 compared with anormal controls 
and bcarcinogenic controls. 
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experimental groups (Fig. 12). Furthermore, lipid metabolome analysis in mouse skin was 
performed by liquid chromatography tandem mass spectrometry (ESI-MS, Fig. 13). We 
confirmed that the main lipid mediator in mouse skin was PGE2, and the production of 
PGE2 and PGD2 in Dioscorea japonica feeding mice decreased to 63.7% and 28.1%, 
respectively, compared with the carcinogenic control. DJE topical application also 
decreased PGE2 and PGD2 production to 62.2% and 28.1%, respectively. Whereas, PGF2 
increased in Dioscorea japonica treatment groups. 
 
Effect of Dioscorea japonica treatment on pathohistological and 
immunohistochemical analyses 
Carcinogenic control mouse epidermis induced exhibited significant epidermal 
hyperplasia with hyperproliferation of the keratinocytes (upper part of HE staining in Fig. 
14). Dioscorea japonica treatment markedly suppressed the epidermal hyperplasia.  
Moreover, infiltration of a lot of inflammatory cells in the epidermis in 
carcinogenic control was substantially inhibited by Dioscorea japonica feeding and DJE 
topical application (lower part of HE staining in Fig. 14). Immunohistochemical analyses 
indicated that COX-2 and mPGES-1 localized in tumor keratinocytes, and, additionally,  
COX-2 was strongly expressed in epidermal dendritic cells (Langerhans cells, LCs), but 
mPGES-1 was not observed in LCs (Fig. 14). Similarly, H-PGDS was also highly 
expressed in LCs, but not in keratinocytes. Interestingly, COX-2 staining was decreased 
in both tumor keratinocytes and LCs by Dioscorea japonica treatment. Additionally, we 
determined the localization of COX-2 and mPGES-1 in the mouse epidermis with 
inflammation and tumorigenesis by double immunofluorescent staining. Consistent with 
immunohistochemical analyses, COX-2 co-localized with CD207 (LC marker) and was 
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present both in cancer cells and LCs. The immunoreaction of COX-2, especially in LCs, 
 
 
Fig. 14. Histochemical analyses in mouse skin. 
Hematoxylin and eosin (HE) staining were pathologically analyzed. Brown-colored 
immunostaining of COX-2, mPGES-1, and H-PGES indicates each localization. Double-headed 
arrows indicate hyperplasia of accumulated cancer cells and arrowheads indicate Langerhans cells. 
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present both in cancer cells and LCs. The immunoreaction of COX-2, especially in LCs, 
 
 
Fig. 15. Double fluorostaining of COX-2, mPGES-1 or CD207 (A), and measurement of 
infiltrating cells in mouse skin (B-D). 
COX-2 and mPGES-1 expressing cells in carcinogenic control mouse epidermis were analyzed by 
immunofluorescent staining (A). COX-2 and CD207 (marker of Langerhans cells) were co-
fluorostained, but mPGES-1 and CD207 were not. mPGES-1 and COX-2 were co-fluorostained in 
carcinogenic keratinocytes. For double immunofluorescent staining, merged signals are shown in 
yellow. The number of infiltrating neutrophils was counted in visualized by immunofluorescent 
staining of Ly-6G/Ly-6C (Gr-1) (green in upper B) and eosinophils were counted after HE staining 
(bottom B). The comparison of their number was represented as mean ± SD of 10 sections per group 
(C and D); *p<0.01 compared with the carcinogenic control. Arrowheads indicate Langerhans cells. 
N.D.; not detected. 
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present both in cancer cells and LCs. The immunoreaction of COX-2, especially in LCs, 
was stronger than that in cancer cells (Fig. 14 and 15A). In contrast, double staining for 
mPGES-1 and CD207, or for mPGES-1 and COX-2 showed that mPGES-1 co-localized 
with COX-2 in cancer cells, but not in LCs (Fig. 15A). Furthermore, we conducted 
immunostaining and HE staining, and counted the number of neutrophils and eosinophils 
to determine the effect of Dioscorea japonica on inflammatory cell infiltration. As shown 
in Figure 15B, the greatest numbers of neutrophils and eosinophils were observed in 
carcinogenic controls. Counting the cells showed that Dioscorea japonica treatment 
decreased the infiltrating perilesional neutrophils and eosinophils to less than 50% and 
20%-35%, respectively (Fig. 15C and D). 
 
 
 
 
Fig. 16. Effects of diosgenin on the expression of Ptgs2 and Ptges in LPS-stimulated RAW264 
cells. 
LPS-stimulated RAW264 were cultured with or without 100 nM diosgenin. mRNA expression of 
Ptgs2 (COX-2) and Ptges (mPGES-1) was measured by quantitative RT-PCR. The expression levels 
are shown as a relative value against control cells without LPS and diosgenin, and are represented 
mean ± SD of 3 separate experiments; p<0.05 compared with aLPS(-)/diosgenin(-) and 
bLPS(+)/diosgenin(-). 
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DISCUSSION 
 
 
In this study, we showed that not only COX-2 but also mPGES-1 was 
overexpressed in squamous cell carcinoma of mouse skin, and they were co-localized in 
proliferated epidermal cancer cells. In addition, COX-2 was highly expressed, but 
mPGES-1 was not present in LCs. According to our results, COX-2 may be involved in 
carcinogenesis, tumor growth, and activation of LCs. On the other hand, main roles of 
mPGES-1 may be proliferation and development of cancer cells. PGE2 specific receptors 
EP1-4 are expressed in normal and tumor epidermis(60,61). In tumors induced by UVB 
light exposure and COX-2 overexpression, EPs localize in epidermal hyperplasia(60,61). 
The signaling pathways of PGE2/EP1 and PGE2/EP3 are involved in immune responses 
of the skin via T helper type (Th) 1 cells and dendritic cells, respectively(62,63). Although 
the presence of EP4 in LCs is immunohistochemically unknown, PGE2/EP4 signaling 
promotes migration and maturation of Langerhans cells, and initiates skin immune 
responses(64). Taken together with our results, it is suggested that the produced PGE2 by 
COX-2 and mPGES-1 induce tumor development and immune responses via the 
individual receptors in the autocrine or paracrine manner in squamous cell carcinoma of 
the skin.  
In addition, H-PGDS was also predominantly expressed in LCs, and which may 
indicate a coupling of COX-2 and H-PGDS and the produced PGD2 regulates LCs activity. 
LCs play a key role in establishment of cutaneous immunity, and participate in squamous 
cell carcinoma(56,65). Human dendritic cells including LCs in the skin express H-PGDS, 
and produce PGD2 in response to various stimuli(66). Thus it is suggested that the produced 
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PGD2 in autocrine manner in LCs is involved in cutaneous immune system and 
inflammatory reactions in the skin. Previous reports indicate the opposing 
immunomodulatory roles of PGD2 receptors, DP and CRTH2 (chemoattractant receptor 
homologous molecule expressed on Th2 cells)(67,68). In inflammatory processes of the skin, 
PGD2 may play a role in the early stages via DP, and in eosinophil migration during the 
late stages via CRTH2. In each process of developing squamous cell carcinoma, further 
studies will be needed to determine the roles of H-PGDS and PGD2 in inflammation and 
carcinogenesis. 
Our recent report demonstrates that Dioscorea japonica suppresses the 
expression of COX-2 and mPGES-1, and has an anti-carcinogenic effect on several model 
cell lines (reference 55 and unpublished data). In the present study, not only application, 
but also ingestion of Dioscorea japonica affects the expression of COX-2 and mPGES-1, 
and leads to decreased PGE2 in vivo. Dioscorea japonica is rich in a lot of nutrients, and 
one of them is a plant steroidal saponin such as diosgenin. Diosgenin has been reported 
to have some preventive effects on mouse colon carcinogenesis(45), mouse squamous cell 
carcinoma(69) and mouse Alzheimer’s disease(70). Our previous study also showed that 
diosgenin suppressed COX-2 in A549 cells(55), and additionally our recent experiment 
showed that it suppressed both of COX-2 and mPGES-1 in LPS-stimulated mouse 
macrophage-like RAW264 cells (Fig. 16). Therefore, diosgenin is likely one of the 
effective substances in the present study, and liposoluble and low molecular diosgenin 
may have effects via the oral and application routes.  
In this study, lipid analysis showed that Dioscorea japonica did not decrease 
PGE2 less than normal control, and therefore it may have no side effects caused by loss 
of homeostatic PGE2. It is unclear about effect on kidney and cardiovascular system, 
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because there are only a few TXB2 and 6-keto-PGF1which are stable metabolites of 
TXA2 and PGI2, respectively, in the mouse skin (data not shown). However, mRNA levels 
of COX-2 and mPGES-1 of Dioscorea japonica-treated groups were not lower than that 
of normal control, which means to keep the production of homeostatic PGE2 without side-
effects. These results suggested that Dioscorea japonica has the possibility of a novel 
preventive agent in inflammation and carcinogenesis. 
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Chapter IV 
Conclusion Remarks 
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Lipid mediator PGE2 is widely distributed in various organs, and is involved in 
several biological phenomena such as inflammation and carcinogenesis. In the PGE2 
synthetic pathway, coupled COX-2 and mPGES-1 are induced at the pathophysiological 
condition, and hyperproduced PGE2. NSAIDs are clinically used for symptomatic relief 
of patient(13). Most NSAIDs inhibit COX-1 and COX-2, and decrease eicosanoids, and 
for that reason, they have some side effects such as gastrointestinal injury(14). Then 
selective COX-2 inhibitors, such as celecoxib and rofecoxib, had developed as a next-
generation NSAIDs. Indeed, the selective COX-2 inhibitors reduce gastrointestinal side 
effects, but exhibit the other side effects on renal and cardiovascular systems(15,71). 
Currently, the terminal enzyme for PGE2 synthesis, mPGES-1, is expected for a new-
generation NSAIDs as a potential drug target(17). For prevention of chronic disease 
including cancer, we try to discover functional foods targeting COX-2 and mPGES-1 
without side effects. 
In this study, we found a novel functionality of Dioscorea japonica with 
suppression of COX-2 and mPGES-1. Dioscorea japonica is one of the wild yams and is 
a relative of the Dioscoreaceae family native to Japan. For many years, it is believed that 
Dioscorea japonica has rich nutrition and some functionalities such as gastric mucosal 
protection and digestive enhancement. Additionally, we demonstrated that Dioscorea 
japonica has the other effects, that is, anti-inflammation and anti-carcinogenesis.  
First, we demonstrated DJE suppressed the expression COX-2 and mPGES-1, 
and also decreased COX activity and PGE2 production in vitro. At least COX-2 expression 
was regulated at transcriptional level with NF-B translocation. Decrease of PGE2 
production by the effects of DJE induced carcinoma cells to apoptosis. To confirm the 
food functionality of Dioscorea japonica against the PGE2-mediated carcinogenesis and 
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inflammation in vivo, we investigated in squamous cell carcinoma of mouse skin exposed 
to DMBA and TPA. Dioscorea japonica-containing feed and DJE-topical application 
suppressed the expression of COX-2, mPGES-1 and inflammatory cytokines, and 
inhibited tumor formation, hyperplasia, and inflammatory cells infiltration. Indeed, the 
lipid analysis also showed that PGE2 and PGD2 decreased by Dioscorea japonica 
treatment. Immunohistochemical analyses showed the immunoreactivities of COX-2 and 
mPGES-1 in tumor keratinocytes and stronger immunoreactivities of COX-2 and H-
PGDS in Langerhans cells. Treatment of Dioscorea japonica decreased the 
immunoreactivity of COX-2 and mPGES-1. These results indicate that Dioscorea 
japonica may have preventive effects on inflammation and carcinogenesis via 
suppression of PGE2 synthesis pathway. The effects are believed to be due at least in part 
to relate to the immune system in the squamous cell carcinoma. In addition, our study 
demonstrated that not only topical application of Dioscorea japonica, but also oral intake 
is effective for anti-inflammatory and anti-carcinogenesis.  
These findings show that Dioscorea japonica is good functional food and might 
be utilized in the preventive foods for PGE2-mediated several pathophysiological 
functions. Our results on the effects of Dioscorea japonica may pave the way for further 
therapeutic methods. Additionally, it is necessary to identify the effective substances from 
Dioscorea japonica, and find the regulation in signaling pathway of COX-2 and  
mPGES-1 expression.   
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